NDA 214701 · Blueprint Medicines
Gavreto
Pralsetinib · Oral
Breakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Dec 1, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 1, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
2 Phase 3, 6 recruiting
FAERS reports
1,824
1,139 serious, 259 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 1, 2020 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review Breakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- GAVRETO · PRALSETINIB 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pralsetinib" as an intervention, any sponsor and status, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
Fudan UniversityAcademic, hospital or other
NCT06195228 · 800 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 31, 2026
Drug: dabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy and 4 more · For: Advanced Thyroid Cancer Patients Who Received Target Therapy
Sites: Fuzhou, China; Zhengzhou, China; Wuhan, China · 8 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03037385 · 590 participants · Start Mar 17, 2017 · Primary completion Mar 21, 2024
Drug: pralsetinib (BLU-667) · For: RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer and 37 more
Sites: Phoenix, Arizona; Orange, California; Aurora, Colorado · 71 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruiting
Fujian Medical UniversityAcademic, hospital or other
NCT07010393 · 335 participants (planned) · Start Jul 1, 2025 · Primary completion Dec 31, 2027
Drug: Dabrafenib; Trametinib and 9 more · For: Thyroid Neoplasms
Sites: Fuzhou, China
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04632992 · 252 participants · Start Jan 13, 2021 · Primary completion Dec 4, 2023
Drug: Entrectinib; Inavolisib and 10 more · For: Advanced Unresectable or Metastatic Solid Malignancy
Sites: Anchorage, Alaska; Oro Valley, Arizona; Hot Springs, Arkansas · 38 sites in all
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04222972 · 223 participants · Start Jul 24, 2020 · Primary completion Jan 27, 2025
Drug: Pralsetinib; Carboplatin and 6 more · For: RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung and 14 more
Sites: Buenos Aires, Argentina; La Rioja, Argentina; St Leonards, Australia · 74 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product prescribing issue194
- death152
- fatigue126
- off label use120
- asthenia117
- anaemia99
- diarrhoea96
- hypertension96
- disease progression91
- blood pressure increased90
- constipation90
- white blood cell count decreased85
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 48 |
| 2021 | 467 |
| 2022 | 275 |
| 2023 | 179 |
| 2024 | 370 |
| 2025 | 323 |
| 2026 | 162 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gavreto (Pralsetinib)
2024 spending
$14.9M
Beneficiaries
159
980 claims
Per beneficiary
$93,739
$182.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $2,558,955 |
| 2022 | $8,399,605 |
| 2023 | $11,030,094 |
| 2024 | $14,904,520 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V, Hu MI, Wirth LJ, et al. · Lancet Diabetes Endocrinol 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF, Curigliano G, Kim DW, et al. · Lancet Oncol 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Hegde A, Andreev-Drakhlin AY, Roszik J, et al. · ESMO Open 2020 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Besse B, Subbiah V, Curigliano G, et al. · J Clin Oncol 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.
Ali MA, Shah SS, Ali R, et al. · Cancer Invest 2023 · Systematic Review
- Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V, Cassier PA, Siena S, et al. · Nat Med 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Blueprint Medicines
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.